A new study published in Cancer Discovery, the journal of the American Association for Cancer Research (AACR), found that combining an epigenetic drug with a common immunotherapy may help fight one of the most aggressive and treatment-resistant cancers — relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL). The novel technique could be a turning point for individuals who have few effective therapy alternatives available. 

The study, led by Drs Jing Tan and Huiqiang Huang from Sun Yat-sen University Cancer Centre and Dr Choon Kiat Ong from the National Cancer Centre Singapore, explored whether a type of drug called a DNA methyltransferase (DNMT) inhibitor could "wake up" the immune system in cancer cells that usually resist treatment. 

The scientists aimed to imitate a viral infection inside the tumour by combining a DNMT inhibitor (decitabine or azacitidine) with an anti-PD-1 immunotherapy (sintilimab). This technique, known as viral mimicry, tricks the body into thinking it is being attacked, triggering a chain reaction that reactivates immune cells against cancer. 

R/R NKTL is a rare and fatal kind of non-Hodgkin lymphoma that primarily affects young adults in East and Southeast Asia. While immunotherapy medicines such as anti-PD-1 antibodies have shown promise, many patients may not respond after a brief improvement. 

Unlike standard chemotherapy, which can induce severe side effects such as nausea, hair loss, and organ damage, epigenetic therapies reprogramme gene expression rather than physically harming cells. Researchers believe that taking a more tailored strategy could not only improve treatment sensitivity but also lessen the long-term detrimental consequences of older cancer medications. 

In the trial, 21 patients with R/R NKTL who had relapsed following anti-PD-1 treatment received the combination therapy. The findings were striking: ten patients obtained complete remission, four showed partial responses, and the two-year overall survival rate was 50.2%, greatly exceeding the standard three-month survival benchmark after relapse. 

Preclinical research in mice confirmed these findings, demonstrating that DNMT inhibitors reactivated dormant viral genes within tumour cells. This mechanism activated the type 1 interferon signalling pathway, causing the body's CD8-positive T cells to attack the malignancy. 

"This new therapy achieves a significantly improved median survival and may even be curative for some patients," disclosed Dr Huang. "By using DNMT inhibitors to trigger viral mimicry, we are effectively turning a 'cold' tumour 'hot'—making it visible to the immune system again." 

Dr Ong further stated that the findings "highlight the potential of epigenetic drugs to reshape immune resistance" and provide a new technique for overcoming immunotherapy failure. 

The authors acknowledged the study's limitations, including its retrospective methodology and small sample size. Large-scale trials of R/R NKTL are difficult due to their rarity, and more study is needed to confirm the results in varied groups. 

However, oncologists regard this strategy as part of a larger transition in modern medicine—away from toxic, one-size-fits-all chemotherapy and towards precision medicines that activate the body's own defence mechanisms with fewer adverse effects. 

If validated in future studies, this epigenetic and immune-based treatment could provide new hope for patients confronting one of cancer's most difficult difficulties.